Ascendis Pharma A/S
ASND
$223.82
-$3.59-1.58%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -254.05M | -255.99M | -293.74M | -367.37M | -410.04M |
| Total Depreciation and Amortization | 19.42M | 18.64M | 18.75M | 18.59M | 18.66M |
| Total Amortization of Deferred Charges | 570.40K | 497.80K | 497.80K | 497.80K | 497.80K |
| Total Other Non-Cash Items | 220.24M | 212.94M | 125.29M | 108.60M | 172.79M |
| Change in Net Operating Assets | 78.39M | -89.90M | -28.83M | 4.00M | -112.81M |
| Cash from Operations | 64.57M | -113.80M | -178.03M | -235.69M | -330.90M |
| Capital Expenditure | -9.67M | -6.13M | -6.62M | -2.07M | -1.55M |
| Sale of Property, Plant, and Equipment | -- | 0.00 | 0.00 | 1.02M | 1.02M |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -1.10K | -1.10K | -1.10K | 7.98M |
| Cash from Investing | -9.67M | -6.13M | -6.63M | -1.05M | 7.46M |
| Total Debt Issued | -- | 0.00 | 134.16M | 134.16M | 134.16M |
| Total Debt Repaid | -21.96M | -18.07M | -14.31M | -11.65M | -11.37M |
| Issuance of Common Stock | 87.08M | 94.05M | 345.16M | 333.05M | 340.43M |
| Repurchase of Common Stock | -28.79M | -28.79M | -28.79M | -28.79M | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -19.29M | -19.29M | -19.29M | -19.29M |
| Cash from Financing | 44.29M | 34.47M | 459.44M | 448.88M | 487.84M |
| Foreign Exchange rate Adjustments | -27.85M | -3.09M | -12.74M | 10.77M | 24.22M |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 71.34M | -88.56M | 262.05M | 222.91M | 188.63M |